Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01012999 · ClinicalTrials.gov registry record · Phase 1
A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain
A Phase 1 study, sponsored by University of Utah.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01012999 is a Phase 1 study that was terminated before completion, run by University of Utah. The registered enrollment target is 16 participants.
The verdict
NCT01012999, a Phase 1 study, was terminated before completion, sponsored by University of Utah.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the appropriate dose and effectiveness of intra-nasal administration of a potent narcotic, sufentanil, for the treatment of moderate to severe pain due to broken bone(s) in the arm or leg.
Interventions
- DRUG sufentanil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01012999
The ClinicalTrials.gov registry entry for NCT01012999 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sufentanil is the first listed.
NCT01012999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01012999 about?
NCT01012999 is a clinical study titled "A Dosing and Efficacy Study of Intra-nasal Sufentanil for Moderate to Severe Pain". The purpose of this study is to determine the appropriate dose and effectiveness of intra-nasal administration of a potent narcotic, sufentanil, for the treatment of moderate to severe pain due to broken bone(s) in the arm or leg.
What is the current status of trial NCT01012999?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2009-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01012999?
The interventions under investigation include: sufentanil (DRUG).
Who is sponsoring clinical trial NCT01012999?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.